Moderate-to-Severe Atopic Dermatitis Refractory to Dilute Bleach Bath Therapy

This protocol applies to patients with moderate or severe atopic dermatitis who did not achieve adequate disease control — specifically a 50% improvement in severity — with dilute bleach baths added to standard topical treatment.

Clinical Scenario

Patient has moderate or severe atopic dermatitis and is refractory to, intolerant of, or unable to use mid-potency or greater topical treatment.

Previous Line — Goals Not Met

Prior therapy: Dilute bleach baths (in addition to topical therapy)
Unmet target: 50% improvement in atopic dermatitis severity within approximately 4 weeks

Next-Line Approach (partial)

The next step involves adding a form of allergen immunotherapy to ongoing standard topical treatment. The specific modality, patient selection criteria, and monitoring parameters are detailed in the complete protocol.

Treatment Goals

Target: 50% or greater improvement in atopic dermatitis severity from baseline. Estimated median time to effect is approximately 5 months.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.anai.2023.11.009

Recommendation 11: In patients with moderate-severe atopic dermatitis, the JTF panel suggests, in addition to topical therapy, dilute bleach baths over usual (no dilute bleach-based) baths (conditional recommendation, low-certainty evidence).

In patients with moderate-severe atopic dermatitis refractory, intolerant, or unable to use mid-potency topical treatment, the JTF panel suggests adding allergen immunotherapy to standard topical treatment over not adding (conditional recommendation, moderate-certainty evidence).

Based on a combination of clinician-reported AD severity (eg, SCORAD), AIT likely improved AD severity by 50% or more from baseline compared with no AIT (40% vs 26%), with similar estimates of effect for SCIT and SLIT.

Crude estimates of median time to effect were 5 (range 1-12) months.

View source ↗